| 24017 |
Alectinib |
Alecensa® |
As adjuvant treatment following complete tumour resection for adult patients with ALK-positive NSCLC at high risk of recurrence. |
Rapid Review complete |
2nd July 2024 |
 |
| 20054 |
Carfilzomib (in combination with daratumumab and dexamethasone) |
Kyprolis® |
In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
NCPE Assessment Process Complete |
3rd July 2024 |
|
| 23048 |
Fenfluramine (Fintepla®) |
Fintepla® |
Fenfluramine (Fintepla®) is indicated for seizures associated with Dravet Syndrome (as an add-on therapy for patients two years of age and older). |
NCPE Assessment Process Complete |
3rd July 2024 |
|
| 24023 |
Iptacopan |
Fabhalta® |
Iptacopan is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. |
Rapid Review Complete |
16th July 2024 |
|
| 24013 |
Pembrolizumab |
Keytruda® |
Pembrolizumab, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung carcinoma (NSCLC) at high risk of recurrence in adults. |
Awaiting full HTA submission from Applicant |
12th July 2024 |
|
| 24026 |
Pemigatinib |
Pemazyre® |
Pemigatinib (Pemazyre®) is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. |
Rapid Review Complete |
16th July 2024 |
|
| 22064 |
Teclistamab |
Tecvayli® |
As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. |
NCPE Assessment Process Complete |
4th July 2024 |
|
